Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0LB6D
|
|||
| Former ID |
DNCL003727
|
|||
| Drug Name |
RG7203
|
|||
| Indication | Schizophrenia [ICD-11: 6A20] | Phase 1 | [1] | |
| Company |
Roche
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Phosphodiesterase 10A (PDE10) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Purine metabolism | |||
| Morphine addiction | ||||
| Pathwhiz Pathway | Purine Metabolism | |||
| Reactome | cGMP effects | |||
| G alpha (s) signalling events | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | Synaptic synopsis. SciBX 6(41); doi:10.1038/scibx.2013.1153. Oct. 24, 2013 | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.